Future needs—diagnostic services  by Nicolas-Chanoine, M.-H.
Future needsÐdiagnostic services
M.-H.Nicolas-Chanoine
Service deMicrobiologie et Hygie© ne, Hoª pital Ambroise, Boulogne, France
As clinical microbiologists and physicians are the two medical
groups in charge of diagnosing and treating infectious dis-
eases, de¢ning future needs in terms of microbiological diag-
nosis requires the points of viewof both.
Diagnosis in clinical microbiology entails the determina-
tion of etiology and, if possible, the determination of the sus-
ceptibility of microorganisms to antimicrobial drugs. Both
types of data are currently very useful for epidemiology but
they contribute little to helping physicians make primary
decisions in individual patient care.
In the community, it is rare that specimens are sampled for
infectious disease diagnosis. Therefore, the great majority of
treatments are empirical.
Although it is common practice in hospital to sample speci-
mens for both in- and outpatients, all outpatients and the great
majority of inpatients are also given empirical treatment. For
inpatients, this treatment can be re-evaluated when the results
of susceptibility testing are available, which is approximately
after 48 h, or sometimes as soon as cultures become positive,
which is approximately after 24 h.
Obviously, such a long delay in obtaining microbiological
data leads to the use of empirical treatments.
F U T U R E N E E D S : O B T A I N I N G M I C R O B I O L O G I C A L
R E S U L T S MO R E Q U I C K L Y
In the current context in which national and international
recommendations are being made with regard to reducing the
use of antibiotics and using them in a more appropriate man-
ner (in order to limit bacterial multiresistance), it is thought
that a shorter delay in obtaining microbiological data might
help physicians in implementing these recommendations.
A supplementary argument which reinforces this feeling
relates to the changes that we can expect in patient demo-
graphics in hospital. An increase in outpatients and an increase
in shorter inpatient stays are forthcoming. Among hospita-
lized patients, wewill see an increase in immunocompromised
patients (surgical, ICU, transplants, oncology, hematology,
geriatrics, neonatology). We can also expect an increase in
opportunistic pathogens and, ¢nally, new and extended
mechanisms of resistance.
As for antibiotic treatment, the crucial point seems to center
aroundwhat is the reasonable length of time needed for physi-
cians to prescribe antibiotic treatments e¡ectively on the basis
of individual microbiological results.
For outpatients, results are needed in real time. To satisfy
this request, clinical microbiologists will never be able to o¡er
other results than those of direct microscopic analysis which,
when they are positive, can only guide the antibiotic prescrip-
tion but not de¢ne it.
For inpatients, the consensus of French physicians belong-
ing to di¡erent medical ¢elds (ICU, emergency, neonatology,
hemato-oncology) is that a reasonable delay should corre-
spond to the time interval between the ¢rst empirical antibio-
tic dose and the second, i.e. 4^8 h.
F U T U RE N E E D S : I M P R O V I N G T H E D I A G N O S T I C
S E N S I T I V I T Y
In addition to shortening the delay before microbiological
results are available, clinical microbiologists are faced with
new challenges. For immunocompromised or fragile patients,
clinical microbiologists need to be able to screen for the pre-
sence of hidden or occult infectious diseases.With the arrival
of immunomodulatory drugs, one question needs to be asked:
are in£ammatory reactions observed in such patients related or
not to infectious diseases?
Despite a better understanding of in£ammatory processes
activated during infection, the severe sepsis syndrome remains
the leading cause of mortality and morbidity in critical care
units [1]. Since the in£ammatory network response varies in
relation to the time course of the disease [2,3], the faster the
infectious origin of in£ammation is established, the better
antimicrobial and immunologic therapycan be adapted.
A N S W E R S I N T H E S H O R T T E R M
Fortunately, clinical microbiologists are not alone in answer-
ing these requests which are often addressed to them by
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physicians. One of their partners is the manufacturer of diag-
nostic devices.
In the very near future, automated machines will be avail-
able that will be able to provide biochemical identi¢cation and
antibiotic susceptibility of 18-h cultures of bacteria in a maxi-
mum of 6 h. This means that 80% of positive bacteriologic
results will be available on the day following sampling.
This can be considered a real advance only if there are: (1)
newwork£ows in the laboratory; (2) possibilities for immedi-
ate transfer of the results by computer networks; and (3) clini-
cians in the wards to receive and use the results promptly. In
such cases, 80% of patients with specimens yielding positive
culture could then be under appropriate antibiotic treatment
on the day following the sampling.
Whereas existing technical and ¢nancial systems can be
readily used to transfer results, new approaches will be
required to carry out changes in work£ow as well as to imple-
ment results more quickly. In fact, as the microbiological
results cannot yet be provided on the day of sampling, micro-
biological technicians, clinical microbiologists and physicians
have to be convinced of the bene¢t for infected patients of
obtaining the results on the day following the sampling.This
conviction will play a fundamental role in bringing together
the principal actors involved.
A N S W ER S I N T H E L O N G T E R M
What can be expected for potentially infected patients with
culture-negative specimens?
The other partners of clinical microbiologists, namely
those involved in microbiological research, may provide new
diagnostic developments for such patients.
Recent publications have shown that free or physiologically
released microbial DNA is present in di¡erent biological £uids
(serum, plasma, amniotic £uid), even if £uid cultures are nega-
tive [4^8], and that this free DNA can be detected by PCR
using either species-speci¢c primers or universal primers, e.g.
primers to amplify16S rRNAgenes [6^9].
In the case of universal primers, the ampli¢cation product
has to be sequenced to identify the species to which ampli¢ed
DNA belongs. This sequencing step limits the use of such an
approach for infectious disease diagnosis in laboratory routine.
The second limitation to this approach is the absence of anti-
microbial drug susceptibility data on the organism from
which the free DNAoriginated.
However, we can hope to overcome these limitations,
thanks to the development of new technologies such as silicon
microchips.
The chip principle consists of directly synthesizing up to
40 000 oligonucleotide probes on one chip. PCRproducts are
put in contact with these probes, which will hybridize with
the complementary DNA strand present in the PCR product.
Therefore, chips containing probes for detecting bacterial 16S
rRNAgenes will be able to identify the species corresponding
to the DNA, which will previously have been ampli¢ed from
serum, e.g. with universal bacterial primers.
A chip can contain only species-speci¢c probes or probes
for identifying resistance-encoding genes (in bacteria or in
viruses) [10].
Chip technology, which appears promising, has, moreover,
the potential for automation in laboratory routine.Therefore,
we can expect, in the long term, new procedures for obtaining
microbiological results.
Indeed, by applying both the PCR and chip methods to
biological £uid specimens, it seems possible to identify a
microorganism and the principal mechanisms of resistance
coded in the DNA after 5 h, a delaywhich is acceptable to phy-
sicians.
Nevertheless, before the arrival of such technology in our
laboratories, clinical microbiologists have to play a leading
role in promoting studies to answer the following clinical
questions:
1. What is the infectious status of free DNA in biological
£uids?
2. Is DNA detectable in the bloodstream only if microorgan-
isms have been circulating in the blood, or, to reformulate the
question, can DNA be released from an infected site without
the release of the infectingmicroorganism into the blood?
3. If it can, how can such sites, whether of super¢cial and/or
deep infection, be identi¢ed?
4. Can simple mucosal colonization be the origin of free
DNA in blood?
Taking into account the fact that genes can be present but
not expressed, it seems important to also answer the following
microbiological questions:
1. What is the frequency of resistance-encoding genes that
are not expressed?
2. Which types of resistance-encoding genes are concerned?
3. Which molecular mechanisms are linked to their expres-
sion (insertion sequence, position in integron sequence,
upmutation)?
This does not exhaust the list of questions, and our convic-
tion is that to answer them it is necessary, without further
delay, to establish cooperation and discussion between manu-
facturers, physicians and clinical microbiologists.
C O N C L U S IO N
Many changes can be expected in the ¢eld of microbiological
diagnosis. Some microbiologists believe that technological
advances perhaps pose a threat to the clinical microbiology
profession. In contrast, others think that technological
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advances can only reinforce the role of clinical microbiologists
in diagnosing infectious diseases. In fact, the more that micro-
biological results become available, the more clinical micro-
biologists will be needed to interpret these results. It seems
that clinical microbiologists remain the most appropriate
interface betweenmicrobes and patients.
R E F ER E N C ES
1. Anonymous. Increase in national hospital discharge survey rates
for septicemiaöUnited States,1979^87.MMWR1990; 39: 31^4.
2. Giroir BP. Mediators of septic shock: new approaches for inter-
rupting the endogenous in£ammatory cascade. Crit Care Med
1993; 21: 780^9.
3. Natanson C, Ho¡manWD, Su¡redini AF, Eichacker PQ, Danner
RL. Selected treatment strategies for septic shock based on pro-
posed mechanisms of pathogenesis.Ann InternMed1994;120: 771^
83.
4. Kawamura S, Maesaki S, Noda T et al. Comparison between
PCR and detection of antigen in sera for diagnosis of pulmonary
aspergillosis. JClinMicrobiol1999; 37: 218^20.
5. Bougnoux ME, Dupont C, Mateo J et al. Serum is more suitable
than whole blood for diagnosis of systemic candidiasis by nested
PCR. JClinMicrobiol1999; 37: 925^30.
6. Laforgia N, Coppola B, Carbone R, Grassi A, Mautone A, Iolas-
con A. Rapid detection of neonatal sepsis using polymerase chain
reaction.ActaPaediatr1997; 86: 1097^9.
7. Kane TD, Alexander JW, Johannigman JA. The detection of
microbial DNA in the blood.AnnSurg1998; 227: 1^9.
8. Hitti J, Riley DE, Krohn MA et al. Broad-spectrum bacterial
rDNA polymerase chain reaction assay for detecting amniotic
£uid infection among women in premature labor. Clin Infect Dis
1997; 24: 1228^32.
9. Ley BE, Linton CJ, Bennett DM, Jalal H, Foot AB, Millar MR.
Detection of bacteraemia in patients with fever and neutropenia
using16S rRNAgene ampli¢cation by polymerase chain reaction.
EurJClinMicrobiol InfectDis1998;17: 247^53.
10. Cockerill III FR. Genetic methods for assessing antimicrobial
resistance.AntimicrobAgentsChemother1999; 43: 199^212.
ãáäNicolas-Chanoine Future needsÐdiagnostic services
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 423±425
